key: cord-0947021-y3pl3mqv
authors: Michos, Athanasios; Tatsi, Elizabeth-Barbara; Filippatos, Fillipos; Dellis, Charilaos; Koukou, Dimitra; Efthymiou, Vasiliki; Kastrinelli, Evangelia; Mantzou, Aimilia; Syriopoulou, Vasiliki
title: Association of total and neutralizing SARS-CoV-2 spike -Receptor Binding Domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine
date: 2021-07-24
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.07.067
sha: b75785f6ef2b12fe09940cc2f484e636520368c0
doc_id: 947021
cord_uid: y3pl3mqv

BACKGROUND: Data regarding the association of antibody levels elicited after immunization with the BNT162b2 mRNA Covid-19 vaccine with epidemiological and clinical parameters are limited. METHODS: We prospectively measured the total (TAbs-RBD) and the neutralizing antibodies (NAbs-RBD) against the receptor binding domain (RBD) of SARS-CoV-2 spike protein in a cohort of 268 Healthcare workers before immunization, 20 days after the 1(st) dose and 30 days after the 2(nd) dose of the BNT162b2 vaccine. A statistical analysis for possible association of antibodies’ levels with epidemiological and clinical parameters was performed. RESULTS: The mean age (±SD) of the participants was 45.45 years (± 11.93) (range: 24-70 years) and 211 (79.9%) were females. Statistically significant differences were detected regarding both TAbs-RBD and NAbs-RBD between the first and second doses of the vaccine (P<0.001). The median (IQR) percentage (%) of NAbs-RBD after the 1(st) dose was 51.07% (31.60%) and after the 2(nd) dose 95.31% (3.70%) (P<0.001).The correlation between the TAbs-RBD and NAbs-RBD was after the 1(st) dose, Spearman’s, rho: 0.861 (P<0.001) and after the 2(nd) dose rho: 0.989 (P<0.001). Twenty days after the 1(st) dose, 56/264 (21.2%) of the participants did not have detectable NAbs-RBD, while one month after the 2(nd) dose all of them had detectable NAbs-RBD. After the 2(nd) vaccine dose, a statistically significant negative association of TAbs-RBD was detected for age (P<0.001), smoking (P=0.011), and immunosuppressive medications (P<0.001), while a positive association was detected for BMI (P=0.004) and systemic adverse events after immunization (P=0.001). CONCLUSION: A significant correlation of TAbs-RBD and NAbs-RBD was detected after both vaccine doses. Older age, smoking, and immunosuppressive medications negatively affected the final antibody level after SARS-CoV-2 immunization. Our findings emphasize the significance of the 2(nd) vaccine dose especially in the older age groups.

The speed of development and approval of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in response to the COVID-19 pandemic represent an extraordinary scientific accomplishment [1, 2] . Several vaccine designs have been developed based on different platforms and mRNA SARS-CoV-2 vaccines were the first to be authorized [3, 4] . Clinical trials as well as post-trials data of the BNT162b2 mRNA Covid-19 vaccine (Pfizer-BioNTech) have been shown that is a highly efficacious and safe vaccine [4] [5] [6] . Data from a mass vaccination program in Israel revealed that the effectiveness of the BNT162b2 vaccine more than 7 days after the second dose was 94% against symptomatic infection and 92% against sever disease with COVID-19 [6] .

However, several questions regarding the immunological response to SARS-CoV-2 vaccines have not been answered yet. Establishing the immunological correlates of protection from SARS-CoV-2 infection and the clinical and epidemiological factors that affecting them are important for public health considerations, evaluation of new vaccines and patient management [7] .

Real world data regarding the association of antibody levels elicited after immunization with the BNT162b2 mRNA Covid-19 vaccine with detailed epidemiological and clinical parameters are limited.

In the present study, we aimed to investigate the association of total and neutralizing antibodies against the receptor binding domain (RBD) of SARS-CoV-2 spike protein with epidemiological and clinical parameters in a cohort of healthcare workers (HCWs) after the 1 st and 2 nd dose of the BNT162b2 vaccine.

This was a prospective cohort study involving healthcare workers (HCWs) of the largest tertiary pediatric hospital in Athens, Greece ("Aghia Sophia" Children's Hospital). The cohort of the study included healthcare professionals (medical doctors, nurses, technicians) and nonmedical personnel of the hospital who were vaccinated for SARS-CoV-2 virus with the Pfizer/BioNTech BNT162b2 vaccine in January 2021 and who were voluntarily tested for their humoral adaptive immune response to SARS-CoV-2 vaccine.

Blood sampling was performed at 3 time points for all participants. The first time point was before the vaccination to investigate the possibility of a past COVID-19 infection, the second was taken 20 days after the 1 st dose of the vaccine administration (1 day before the 2 nd dose) and the third one month after the 2 nd dose. The determination of seropositivity and neutralization activity of antibodies were conducted in the Infectious Diseases Laboratory, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital.

A form containing demographic and clinical data as well as adverse events (AEs) after each COVID-19 vaccination dose was completed by each participant. Data included gender, age, blood type and rhesus, smoking, Body Mass Index (BMI; underweight ≤ 18.5 kg/m 2 , Normal weight = 18.5-24.9 kg/m 2 , overweight = 25-29.9 kg/m 2 and obesity ≥ 30 kg/m 2 ), history of underlying diseases (cardiac, pulmonary, hyperlipidemia and hypertension Type 1 diabetes mellitus, Hashimoto's thyroiditis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, autoimmune hepatitis etc.), allergies (to any kind of allergen and in any manner of manifestation), use of immunosuppressive medications and history of pneumococcal or influenza vaccination within the last three months. Local AEs including pain, edema, pruritus, erythema, or systemic AEs such as fatigue, fever, headache, lymphadenopathy, myalgias, arthralgias etc., were also recorded after each dose of the vaccine.

The study protocol was approved by the scientific and bioethics committee of "Aghia Sophia" Children's Hospital and informed consent was obtained from all participants.

Serum samples were tested using the Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Basel, Switzerland) reagent on a Cobas e 411 immunoassay analyzer for the semiquantitative detection of TAbs-RBD (IgA, IgM and IgG) of S1 subunit of SARS-CoV-2 spike protein according to the manufacturer's instructions.

The Elecsys® Anti-SARS-CoV-2 S is an Electrochemiluminescence Immunoassay (ECLIA), which is based on a double-antigen sandwich Enzyme-linked Immunosorbent Assay (ELISA) methodology. Values of ≥ 0.8 U/ml are positive.

Determination of anti-RBD neutralization titers were conducted using the commercially available and 

Absolute and relative frequencies (%) were used to describe the qualitative variables such as demographic characteristics, while mean, standard deviation (SD), median (Mdn), and interquartile range (IQR) were used for quantitative data. Differences between two or more independent samples

were assessed with Mann-Whitney U test or Kruskal-Wallis H test, respectively. Post-hoc analysis was performed using Tukey-Kramer's test. Spearman rho correlation coefficient was used for associations 

A total of 268 HCWs who had 2 doses of the BNT162b2 vaccine according to the recommended schedule (21 days apart) were included in the study analysis. Four participants had previously confirmed SARS-CoV-2 infection and their antibody response was analyzed separately. The mean age (±SD) of the participants (n=264) was 45.45 years (± 11.93) (range: 24-70 years) and 211 (79.9%) were females. The mean (±SD) BMI of the participants was 24.68 (±4.20), 67 (25.8%) were smokers, 121 (46.5%) had history of underlying diseases and 6 (2.3%) were taking immunosuppressive medications. and 28.73%), myalgias (7.46% and 25%) and fever (1.11% and 19.78%). An enhancement of systemic AEs was noticed after the 2 nd dose of vaccine. There was not any serious allergic reaction among the participants. Most serious AEs included a 45-year-old man who experienced Bell's palsy 20 days after the 2 nd dose and a 60-year-old woman who experienced serious tinnitus with temporary hearing loss 5 days after the 1 st dose that lasted for over a month, with its intense being increased after the 2 nd dose that finally responded to systemic use of corticosteroids.

Statistical differences were found between the TAbs-RBD after the 1 st and 2 nd vaccine doses (P<0.001);

TAbs-RBD after the 1 st vaccine dose were median (IQR): 31.13 (63.59) U/ml, while one month after the 2 nd dose were 1288.00 (1376.95) U/ml ( Table 1) 

There was not a statistically significant difference in immune response between genders regarding either TAbs-RBD or NAbs-RBD for both vaccines' doses (Table 1 ). In contrast statistically significant differences among different age groups were detected with younger age groups having higher TAbs-RBD and NAbs-RBD especially when compared with participants > 60 years old (Table 1 and Figure 1) . A negative correlation of antibody response with age was detected for both vaccine doses regarding both TAbs-RBD and NAbs-RBD (Supplementary Table 2 ).

HCWs who were smokers had a statistically significant lower antibody response for TAbs-RBD and NAbs-RBD after both the 1 st and 2 nd vaccine doses (P=0.033, P=0.015, P=0.041, P=0.002 respectively). Medical history of underlying diseases was associated only with lower NAbs-RBD after the 1 st dose (P=0.010) but did not affect the final antibody response (Table 1 ). In contrast, HCWs who were receiving immunosuppressive medications (n=6) elicited lower levels of TAbs-RBD and NAbs-RBD after both doses (Table 1 ). There was not any significant correlation of elicited antibody response with weight or BMI (Supplementary Table 2 ). Non-significant associations with a history of seasonal flu or pneumococcal immunization, allergies, or blood group type were detected (data not shown).

Number and type of local AEs did not associate with the levels of TAbs-RBD and NAbs-RBD (Table 2) .

However, participants who experienced three or more systemic AEs elicited higher final levels of TAbs-RBD and NAbs-RBD than HCWs who experienced one or they did not have systemic AEs (Table 2) .

Multiple linear regressions for parameters associated with the levels of NAbs-RBD were established for NAbs-RBD after the first and second vaccine dose (Table 3) During the study analysis period, almost 40 days after the 2 nd vaccine dose, two participants with good levels of neutralizing antibodies (800 U/ml and 700 U/ml respectively) developed confirmed SARS-CoV-2 infection with mild self-limited symptoms including low grade fever and nasal congestion for 2 days.

In the present study, we aimed to detect possible associations of total and neutralizing antibodies against the receptor binding domain (RBD) of SARS-CoV-2 spike protein with epidemiological and clinical characteristics after immunization with the 1 st and 2 nd doses of the BNT162b2 vaccine. A good correlation of TAbs-RBD and NAbs-RBD was detected after both vaccine doses. Detection of TAbs-RBD is less costly and easier to measure compared to NAbs-RBD and may be a good substitute in population Abs screening is required after SARS-CoV-2 immunization.

Given the current global vaccine shortage, some researchers have proposed the delay of the administration of the 2 nd vaccine dose to ensure partial immunity to more individuals [8] . In the present study, twenty days after the 1 st dose, a significant percentage of the participants (21.2%) did not have detectable NAbs-RBD, while 1 month after the 2 nd dose all of them mounted NAbs-RBD. Our findings support the timely administration of the 2 nd vaccine dose especially in the older age groups.

Parameters in the present study that negatively affected the final antibody level after SARS-CoV-2 immunization were older age, smoking, and immunosuppressive medications. Recent studies have detected a negative association of age with NAbs-RBD, which is in accordance with our results, but also a sex dependent response, which was not the case in our study [9] .

To the best of our knowledge this is the first study associating smoking status with lower TAbs-RBD as well as NAbs-RBD responses after both doses of BNT162b2 vaccine, which was detected in the singlefactor analysis and confirmed in the regression analysis of the study parameters. Further studies are required to confirm the finding and form a pathophysiologic basis for this finding.

Recent studies have shown that seropositive people after SARS-CoV-2 infection, who receive a single dose of BNT162b2 vaccine, mount much higher antibody responses (also detected in our study) that may be sufficient to prevent infection [10, 11] . However, whether a single dose of mRNA vaccine provides adequate induction of T-cell responses and effective long-term protection in seropositive persons requires further investigation [12, 13] .

Emerging variants of SARS-CoV-2 are of clinical concern and vaccine breakthrough infections with SARS-CoV-2 variants in previously fully immunized individuals have been described [14] . These SARS-CoV-2 variants could have a direct impact on the available COVID-19 vaccines, as they can alter the neutralizing activity of vaccine-elicited antibodies resulting in variable loss of efficacy [15, 16] . However, it is not clear in such cases if it is the lower neutralizing activity of SARS-CoV-2 antibodies, inadequate T-cell responses, or genetic novelty of SARS-CoV-2 variants that caused these infections. In our cohort, two participants with good levels of NAbs-RBD developed mild self-limited COVID-19 infection.

Defining immunological correlates of protection and a protective antibody threshold would be important for public health decisions and for the development of new SARS-CoV-2 vaccines, as they can substitute large and costly field efficacy trials with smaller immunogenicity-based phase 3 trials [7, 17] .

The administration of the BNT162b2 vaccine had a good safety profile in our cohort with most vaccinees developing local self-limited reactions and limited systemic reactions that were more frequent after the 2 nd vaccine dose. Indeed, experiencing 3 or more systemic AEs was associated with higher NAbs-RBD after the 2 nd vaccine dose, possibly indicating higher immune induction. There was not any serious allergic or anaphylactic reaction, while there was one episode of Bell's palsy and one episode with serious tinnitus and deafness that could not be determined if they were vaccine related. It is important after the emergent authorization of COVID-19 vaccines, to maintain public confidence for the safety of immunization with post-vaccination surveillance and documentation of AEs, to achieve high immunization coverage [18, 19] .

Limitations or present study include that there was a limited number of participants with previous SARS- <.001 a,b,c,d,e,f  .001 a,b, 

The story behind COVID-19 vaccines

The lightning-fast quest for COVID vaccines -and what it means for other diseases

SARS-CoV-2 Vaccines

BNT162b2 mRNA COVID-19 Vaccine: First Approval

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Correlates of protection from SARS-CoV-2 infection

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines (Basel)

Emergency Use Authorization of Covid Vaccines -Safety and Efficacy Followup Considerations

Maintaining Safety with SARS-CoV-2 Vaccines